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Summary The expression of urokinase-type plasminogen activator (uPA) was investigated in squamous cell
carcinoma of the human larynx. For this purpose, tissue extracts from 25 matched samples of normal mucosa
and neoplastic larynx were compared for the levels of uPA activity as evaluated by a chromogenic PA assay
and sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography. Also, uPA
antigen was quantified by enzyme-linked immunosorbent assay (ELISA) in 19 cases. The results demonstrate a
significant increase in the levels of uPA activity and protein in tumour tissue extracts, more pronounced in
tumours with lymph node metastases. Immunohistochemistry performed on 70 biopsies showed that uPA
positivity is present both in neoplastic cells and in fibroblast-like cells and macrophages. However, depending
on the histological grading and invasive capacity of the tumour, a pronounced intra- and intertumoral
heterogeneity in uPA staining was observed. In situ hybridisation confirmed the presence of uPA mRNA in
both tumour and stromal cells. The present study provides experimental evidence for a role of uPA in the
invasive growth of human laryngeal carcinoma.
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Degradation of the extracellular matrix and other tissue
barriers by proteases is a prerequisite for neoplastic growth
and metastasis (Mignatti and Rifkin, 1993). Plasminogen
activators (PAs) are serine-proteases which convert plasmino-
gen to plasmin and regulate intravascular fibrinolysis and
extracellular proteolysis. There are two types of PAs, tissue-
type PA (tPA) and urokinase-type PA (uPA), which differ in
molecular weight, immunological reactivity, enzymatic
properties and genomic sequence (Dan0 et al., 1985).
uPA is considered to play an important role in different
processes where extracellular proteolysis is required, including
cell migration, tissue remodelling during development,
angiogenesis and invasive growth in normal and pathological
conditions. In particular, several malignant tumours, e.g.
carcinoma of the colon (Kohga et al., 1985; De Bruin et al.,
1987a, b; Sim et al., 1988; Nishino et al., 1988; Pyke et al.,
1991), lung (Markus et al., 1980; Sappino et al., 1987), breast
(Sumiyoshi et al., 1992), uterus (Whitney et al., 1985;
Sugimira et al., 1992), urinary bladder (Hasui et al., 1989;
1992) and skin (Sappino et al., 1991), express high levels of
uPA compared with normal tissue. Numerous findings
indicate that uPA is involved in tissue degradation during
invasive growth by promoting breakdown of extracellular
matrix proteins either by a direct action of plasmin or
through a plasmin-mediated activation of latent collagenase
(Ossowski et al., 1983, 1988; Mignatti et al., 1986; Saksela
and Rifkin, 1988).
Previous observations had demonstrated a role for uPA in
the in vitro invasive capacity ofcell lines isolated from human
squamous carcinoma of the oral cavity (Clayman et al.,
1993). Also, the determination of uPA antigen performed in
the same study on a limited set of patients suggested a
possible up-regulation of uPA expression in human laryngeal
carcinomas in situ. On this basis, we decided to investigate
more extensively the expression of uPA in the carcinoma of
human larynx. In the present study, matched samples of
normal mucosa and neoplastic laryngeal tissue were
compared for levels of uPA activity and antigen, uPA
localisation by immunohistochemistry, and uPA mRNA
expression by in situ hybridisation. The findings demonstrate
a significant increase in the levels of uPA activity and protein
in the extracts of human laryngeal carcinoma, the extent of
uPA up-regulation being related to the metastatic potential of
the tumour. Accumulation of uPA antigen and mRNA was
observed both in neoplastic and stromal cells. Our data point
to a role for uPA in the invasive growth of human laryngeal
carcinoma.
Materials and methods
Laryngeal biopsies
Matched samples of normal mucosa and neoplastic laryngeal
tissue were obtained from 70 patients who underwent total
(n = 32) or supraglottic (n =38) laryngectomy for laryngeal
carcinoma. The normal mucosa sample was taken at least
3 cm from the neoplastic lesion. Samples showing large areas
of necrosis were excluded from the study. Tissues were
collected immediately after surgical removal and divided in
two parts: one part was frozen at - 70°C for the
determination of uPA activity and antigen; the other one
was fixed in 4% (w/v) paraformaldehyde for immunohisto-
chemical studies and for in situ hybridisation. The
histological diagnosis, performed on traditionally haematox-
ylin-eosin stained sections, identified the tumours as G1
(n = 15), G2 (n = 30) and G3 (n =25) squamous cell
carcinomas according to the International Union Against
Cancer-modified Broders' system and confirmed the absence
of lesions in normal mucosa samples. Lymph node metastases
were present in 30 cases. All 70 matched normal and tumour
biopsies were examined for uPA immunostaining. Twenty-
five GI, G2 and G3 matched samples (11 from metastatic
tumours and 14 from non-metastatic tumours) were also
examined for uPA levels by enzymatic activity assay and
sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) zymography. Nineteen out of the 25 samples
were evaluated also by uPA enzyme-linked immunosorbent
assay (ELISA) (7 from metastatic tumours and 12 from non-
metastatic tumours). Finally, eight matched biopsies were
analysed by in situ hybridisation.
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Preparation of tissue extracts and PA activity assay
Frozen biopsies were thawed and homogenised in 1 ml of
lysis buffer (0.05% Triton X-100/60 mM Tris-HCl, pH 8.5)
per g of fresh tissue. Samples were centrifuged at 12 000 xg
for 30 min at 4°C, and the supernatants were stored at
-80°C until analysis. Protein concentration of the soluble
extracts was determined by coomassie protein assay reagent
(Pierce Europe, The Netherlands).
To evaluate the levels of tissue-associated PA activity,
30 ,ug of the tissue extracts were incubated in a 96-well
microtitre plate with 42 nmol of the plasmin chromogenic
substrate H-D-norleucyl-hexahydrotyrosil-lysine-p-nitroani-
lide-diacetate and 3 ,ug of purified human plasminogen
(American Diagnostica, Greenwich, CT, USA) in 150 Mul of
lysis buffer (Presta et al., 1989). After incubation at 37°C, the
plate was read at 405 nm with an automatic microplate
reader. A standard curve of human uPA (Calbiochem, La
Jolla, CA, USA) was included in each assay.
SDS-PAGE zymography and uPA ELISA
For determination of the molecular weight of the PA activity
in normal and neoplastic larynx, tissue extracts (700 Mug of
total protein) were run on SDS-10% polyacrylamide gel
under non-reducing conditions. Then, proteins were electro-
phoretically transferred from the gel to a nitrocellulose
membrane for 2 h at 400 mA in 40 mm sodium phosphate
buffer, pH 6.5. Zymography of the proteins transferred to the
membrane was carried out on a casein-agarose gel as
described (Colombi et al., 1986). Control gels were made in
the absence of plasminogen to identify plasminogen-
independent caseinolytic activities.
To evaluate the levels of uPA antigen, 50 Mg of the tissue
extracts were analysed by the IMUBIND uPA ELISA kit
(American Diagnostica) according to manufacturer's instruc-
tions.
Immunohistochemistry
Specimens were fixed with 4% paraformaldehyde for 2 h at
4°C and cryoprotected through 5 h intervals of graded
sucrose concentrations (5-30%) in phosphate-buffered
saline (PBS). After embedding in OCT compound, samples
were frozen, cut at 4 gm thickness using a freeze-microtome,
and mounted on chrome-alum-gelatin-coated glass slides.
After three rinses in 1% Triton X-100/PBS, sections were
incubated for 30 min with 0.3% hydrogen peroxide in
methanol to quench endogenous peroxidase activity. Slides
were then washed three times for 10 min each in 1% Triton
X-l00/PBS, followed by a 30 min incubation at room
temperature with 20% normal rabbit serum (Dakopatts,
Denmark) in PBS to reduce non-specific background
staining. After two rinses in PBS, sections were incubated
overnight at 4°C with goat polyclonal anti-human uPA
antibody (60 Mg ml-1 in PBS; Biopool, Sweden) or goat
polyclonal anti-human tPA (12 Mg ml-1; Biopool), followed
by 1 h incubation at room temperature. Sections were washed
with PBS and incubated for 45 min with biotinylated rabbit
anti-goat IgG (1:300) at room temperature. Formation of
the antigen-antibody complexes was demonstrated with
avidin-biotin-peroxidase complex (Dakopatts, Denmark),
and bound peroxidase was developed with 3-amino-9-ethyl-
carbazole (Sigma) in acetate buffer, pH 5.2, added with
hydrogen peroxide. The slides were lightly counterstained
with haematoxylin and mounted.
The specificity of immunostaining was verified by: (1)
omission of the first, second or third layer of antiserum; (2)
substitution oftheprimaryantibodywithnon-immuneIgG;and
(3) absorption of the primary antibody with highly purified
antigen coupled to Sepharose beads. The results obtained with
thepolyclonal anti-uPA antibody wereconfirmed in 20 casesby
staining of adjacent sections with a monoclonal anti-uPA
antibody (Ab no. 3689, American Diagnostica).
In situ hybridisation
The probe used was a 1.3 kb SmaI/BamHI fragment obtained
from the pcUK176 recombinant plasmid harbouring the
human uPA cDNA (provided by P Mignatti, University of
Pavia). The probe (500 ng) was labelled to a specific activity
of 1.5 x 107 c.p.m. jg-' by using the random primed DNA
labelling method according to supplier's instructions
(Molecular Biology, Boehringer Mannheim) in the presence
of 6 gM [3H]dATP (92 Ci mM-1) (Amersham, Buckingham-
shire, UK) and 6 gM each of unlabelled dCTP, dGTP and
dTTP. The probe was separated from unincorporated
nucleotides by precipitation with ethanol, dried and
dissolved in the hybridisation buffer.
Routinely processed, paraformaldehyde-fixed sections were
subjected to in situ hybridisation according to Moro et al.
(1992). Briefly, slides were sequentially immersed twice in
PBS for 10 min, once in 1 Mg ml-' proteinase K dissolved in
2 mM calcium chloride/10 mM Tris-HCl, pH 7.4, for 8 min at
37°C, and twice in 2 Mg ml-' glycine in PBS for 3 min.
Sections were then acetylated in freshly prepared 0.25%
acetic anhydride in 0.1 M triethanolamine-HCl, pH 8.0, for
10 min (Hayashi et al., 1978). Finally the slides were washed
twice in PBS for 3 min, dehydrated in 50%, 75%, 95% and
100% ethanol, 5 min for each passage, and air-dried. The
hybridisation was performed in a mixture containing
1 Mg ml-1 3H-labelled probe prepared according to Moro et
al. (1992), heated at 70°C for 10 min and cooled in ice.
Aliquots (30 Ml) were applied onto each section and
incubated at 42°C for 16-18 h. Slides were rinsed four
times in 50% formamide/ 2 x SSC for 15 min at 39°C and
twice in 1 x SSC for 30 min at room temperature. Auto-
radiography was performed by dipping the slides into Kodak
NTB2 emulsion, air-drying for 2 h in the dark, and storing
for 4 weeks in'sealed boxes at 4°C. Slides were developed in
Kodak D19 developer, fixed in Kodak fixer, rinsed in water,
air-dried, stained with haematoxylin-eosin and mounted
with glycerol-gelatin. For each specimen, controls included
incubation with pBR322-labelled probe or with hybridisation
mix only.
Image anslysis
The Magiscan image analysis system (Joyce Loebl, Gates-
head, UK) was used to perform semi-quantitative evaluation
of the hybridisation signals, according to Moro et al. (1992).
Briefly, the section image was input via a TV camera
mounted on a Nikon light microscope, digitalised on the
high resolution monitor and stored within the Magiscan's
image memory. Five fields were chosen at random and
analysed per slide. The ratio between the integrated density
values of the area of the hybridisation grains and of the
selected surface was determined for each field and non-
specific hybridisation signals were subtracted from all values.
This procedure has been used previously to quantify gene
expression both in cultured cells and in histological sections
(Moro et al., 1990, 1992; Colombi et al., 1991, 1993).
Statistical analysis
Student's t-test was used for comparison of the levels of PA
activity, uPA antigen or uPA hybridisation signals among
normal and tumour samples. Values are expressed as
mean+s.e.m.
Results
uPA levels in laryngeal tumours
To evaluate the modifications of uPA activity that follow the
transformation of human larynx, matched samples of normal
and tumoral laryngeal tissues were analysed in 25 out of the
70 patients examined. PA activity was determined in tissue
extracts with a plasmin chromogenic assay and expressed as
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Committee on Thrombolytic Agents (CTA) Units mg-1 of
protein (Figure la). Preliminary experiments had indicated
that PA activity of laryngeal tissue extracts was abolished by
preincubation of the samples with 1 mM amiloride (Vassalli
and Belin, 1987), thus confirming its identity with uPA
activity (data not shown). uPA activity was higher in the
extracts of laryngeal carcinomas than in matched normal
tissues. It should be noted that uPA activity was equal or
below the limits of detection of the assay (0.1 U mg-' of
protein) in 16 normal tissue extracts but only in two tumour
extracts (for statistical analysis uPA activity in these samples
was assumed to be equal to 0.1 U mg-' of protein). The
mean value+s.e.m. of uPA activity in the cancer group was
0.88+0.21 U mg-1 of protein, five times higher than in the
normal group (0.17+0.03 U mg-1 of protein; P<0.01).
Interestingly, the levels of uPA activity were significantly
higher in the extracts of primary cancers with positive lymph
node involvement (n=11) than in those of non-metastatic
tumours (n= 14) (1.35+0.42 vs 0.51+0.12 U mg - of protein
respectively; P<0.05). No significant differences in uPA
activity levels were observed when tumours were compared
according to their histological grading (0.42 +0.20,
1.00+0.32 and 0.86+0.19 U mg-' of protein for GI, G2
and G3 tumours respectively).
Analysis of tissue extracts by SDS-PAGE, combined with
detection of PA activity by zymographic assay on casein-
agarose gel, was used to confirm the identity of the type of
PA produced by normal and neoplastic larynx. Purified
human uPA and tPA were used as standards. As shown in
Figure 2, zymography of normal and tumoral laryngeal tissue
extracts revealed a major lytic band with an apparent
molecular weight of 53 000, comigrating with the uPA
standard. The band was not apparent when plasminogen
W.
N T N T was omitted from the casein-agarose gel (data not shown),
thus confirming its identity with uPA. No lytic bands
comigrating with the tPA standard were observed in normal
or cancer tissue extracts. In agreement with the chromogenic
PA activity assay, SDS-PAGE zymography confirmed that
uPA activity was significantly higher in tumoral than in
matched normal tissue extracts for all the patients examined
and that the diagnosis of positive lymph node involvement
was characterised by the highest levels of uPA activity
(Figure 2).
To assess whether the increased levels of uPA activity
detected in tumour samples reflected an increase in uPA
antigen content, an ELISA was used on 19 out of the 25
matched biopsies analysed above. As shown in Figure lb, the
kDa
100 -
42 -
N T MT
N T N T Figure 2 Casein- agarose zymography of laryngeal tumour
extracts. Tissue extracts (700Mg of protein) were run on SDS
10% polyacrylamide gel. Zymography of the proteins transferred
Figure 1 uPA in human laryngeal tumours. Paired samples of to nitrocellulose membrane was carried out on a casein-agarose
normal (N) and tumoral (T) laryngeal tissue extracts were gel containing human plasminogen. The migration of purified
evaluated for uPA activity with a chromogenic assay (a) and human uPA and tPA run on a parallel gel is shown by arrows.
for the levels of uPA antigen by ELISA (b). Patients with non- No lytic bands were observed when plasminogen was omitted
metastatic tumours were compared with patients bearing tumours from the gel. N, normal larynx; T, non-metastatic tumour; MT,
with lymph node involvement. metastatic tumour.
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levels of uPA antigen were higher in the extracts of laryngeal
carcinomas than in matched normal tissues (0.27+0.05 vs
1.72+0.31 ng uPA per mg of protein for control and tumour
biopsies respectively; P<0.01). It must be pointed out that a
linear relationship was found when the levels of uPA antigen
measured in each tumour biopsy were plotted against the
corresponding levels of uPA activity (r=0.87. P<0.01). Also,
in agreement with the uPA activity data, the levels of uPA
antigen were significantly higher in primary cancers with
positive lymph node involvement (n= 7) than in non-
metastatic tumours (n= 12) (2.62+0.44 vs 1.19+0.35 ng
uPA per mg of protein respectively; P<0.02). while no
significant differences were observed among biopsies from
tumours with different histological grading (data not shown).
In conclusion, our data indicate that the transformation of
normal laryngeal mucosa to neoplastic tissue is associated
with an increase in tissue levels of uPA. This increase appears
to be related to the metastatic potential of the tumour but
not to its histological grading.
Immunolocalisation of uPA
The immunostaining pattern with polyclonal anti-uPA
antibody was evaluated in cryostat sections from all 70
biopsies of normal larynx and paired laryngeal squamous cell
carcinomas. Staining controls included deletion ofthe various
antibody layers, the use of non-immune IgG, and the use of
antibody preparations absorbed with highly purified prepara-
tions of the corresponding antigen coupled to Sepharose
1171
beads. The controls were negative in all cases. In selected
cases. uPA immunostaiming was confirmed by using a
monoclonal anti-uPA antibody (see Materials and methods).
In normal laryngeal mucosa. a weak staining for uPA was
found in epithelium and in a few fibroblast-like cells and
macrophages (not shown). In laryngeal carcinoma, uPA
immunoreactivity was distributed heterogeneously both in
metastatic and non-metastatic tumours (Figure 3a-d). In
detail, we observed that in 12 out of the 15 Gl tumours
examined most of the cellular nests were positive for uPA
staining (Figure 3a), while in remaining Gl tumours and in
all G2 tumours examined cellular nests characterised by a
strong uPA staining and areas completely devoid of uPA
immunoreactivity were present within the same biopsy
(Figure 3b). Interestingly, in these cases the most intense
reaction was usually detectable in tumour cells that appeared
to. be well differentiated according to histological criteria,
whereas positivity decreased in poorly differentiated cells
(Figure 3b). IN G3 tumours, uPA positivity was mainly
localised in areas with invasive growth and degradation of
surrounding tissue (Figure 3c). Despite this heterogeneity. a
general feature of the larynx tumours examined was that
primary tumours with lymph node involvement were
characterised by a more intense uPA staining in the
cytoplasm of tumour cells than that observed in non-
metastatic tumours. Also. stromal fibroblast-like cells and
macrophages showed uPA positivity in all tumours
independently of the histological grading and lymph node
involvement (Figure 3d).
--,. -av +-.
Fugae 3 Immunohistochemical localisation of uPA in human
laryngeal tumours. Cryostat sections were stained with polyclonal
anti-uPA antibody as described in Materials and methods. (a)
Highly differentiated tumour in which all cells within the nests
show an intense cytoplasmic uPA staining (original magnification:
10 x). (b) Moderately differentiated tumour in which uPA is
detectable only in the most differentiated cells (original
magnification: 25 x). (c) uPA staining associated with the
invasive front of a G3 tumour (arrows, original magnification:
16 x). (d) Numerous uPA-positive cells (arrows) in peritumoral
stroma with inflammatory infiltrate (original magnification: 25
x ).
Fgae 4 Localisation of uPA mRNA in human laryngeal
tumours by in situ hybridisation. Hybridisation was performed
on cryostat sections by using a 3H-labelled uPA cDNA probe.
Low expression of uPA mRNA is detectable in normal epithelium
(b). Higher levels of uPA mRNA expression are present in
tumour cells (c). Specificity of the hybridisation is evident from
the absence of hybridisation in slides incubated with control
pBR322 probe (a). Original magnification: 63 x.uPA up-regulation in laryngeal carcinoma
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When samples were analysed for tPA immunoreactivity,
positivity was limited to capillary endothelial cells in both
normal and malignant tissue. No tPA staining was located in
neoplastic cells (data not shown).
uPA mRNA expression in laryngeal cancer using in situ
hybridisation
To identify the cell types responsible for uPA production in
laryngeal carcinoma, in situ hybridisation with a specific
human uPA probe was performed in eight cases of normal
larynx and corresponding laryngeal carcinoma of different
histological grading. In all cases examined, neoplastic cells
expressed uPA mRNA (Figure 4). Hybridisation grains were
also observed in fibroblast-like cells and macrophages in the
tumoral stroma, whereas endothelial cells were negative (data
not shown). Semi-quantitative evaluation of uPA mRNA
levels was attempted by computerised image analysis of the in
situ hybridisation signals according to Moro et al. (1992).
The results demonstrate a significant increase in uPA mRNA
expression in tumour samples (integrated density per unit
area equal to 5.2+0.8 vs 1.5+0.2 in tumour vs normal
samples, P<0.01). These data, even though obtained on a
limited number of cases and with a semi-quantitative method,
suggest that the increased levels of uPA antigen detected in
tumour samples depend, at least in part, on an increased
expression of uPA gene. Further experiments are necessary to
confirm this hypothesis.
Discussion
Our findings demonstrate that uPA is up-regulated in the
squamous cell carcinoma of human larynx. Increased levels
of uPA activity and protein were detectable in the extracts of
all tumours examined when compared with normal tissue
obtained from the same patients. uPA immunostaining was
present in tumour cells as well as in macrophages and
fibroblast-like cells of the tumour stroma. Accordingly, in situ
hybridisation showed uPA gene expression to occur both in
parenchymal and stromal cells. At variance with uPA, no
modifications in activity levels or immunostaining were
observed for tPA in laryngeal carcinoma. tPA remains
confined to the endothelium and tumour cells do not express
it. Thus, the increased fibrinolytic potential observed in
laryngeal carcinomas is a result of uPA up-regulation. This is
in keeping with the general observation that tumour cells
produce mainly uPA, with few exceptions represented by
melanoma, neuroblastoma and certain leukaemia cells
(Wilson et al., 1980; Rijken and Collen, 1981; Neuman et
al., 1989).
It was demonstrated in the early 1970s that the
transformation of cultured cells by oncogenic viruses
caused a significant increase in the production of uPA
(Ossowski et al., 1973; Goldberg, 1974; Unkeless et al.,
1974). Since then, several observations in vitro and in vivo
have linked the expression of uPA to the transformed state.
For instance, tumour tissue extracts from carcinomas of the
colon, breast, lung and bladder all contained more uPA
antigen and/or activity than did their normal counterparts
(Markus et al., 1980; Corasanti et al., 1980; Camiolo et al.,
1981, 1984). Interestingly, different immunohistochemical
studies have shown that uPA is localised in invading areas
of the tumour, supporting the hypothesis of a role for uPA
in tumour cell invasion (Skriver et al., 1984; Kohga et al.,
1985; Kristensen et al., 1990). Indeed, neutralising anti-uPA
antibodies have been demonstrated to inhibit tumour cell
invasion in different experimental models in vitro and in
vivo (Ossowski and Reich, 1983; Hearing et al., 1988). Also,
a positive relationship between uPA up-regulation in
primary tumour and the presence of lymph node
metastasis has been demonstrated for different neoplasms,
including lung cancer (Sappino et al., 1987), breast
carcinoma (Sumiyoshi et al., 1991) and cervical cancer of
the uterus (Sugimira et al., 1992). Here, we have shown
that levels of uPA activity and uPA antigen in tumour
extracts were significantly higher in laryngeal tumours with
lymph node metastasis than in non-metastatic tumours,
suggesting a possible correlation among uPA expression,
invasiveness and metastatic potential in human laryngeal
carcinoma. Indeed, we have observed uPA immunoreactiv-
ity in invasive areas of G3 laryngeal tumours. These
observations are in keeping with previous findings on the
role of uPA in mediating the capacity of cultured
squamous cell carcinoma cell lines to invade a reconsti-
tuted extracellular matrix (Matrigel) in an in vitro assay
(Clayman et al., 1993). Thus, our results further support a
positive correlation between uPA production, infiltrative
growth and metastatic ability of human tumours, indicating
that uPA up-regulation may be considered a parameter of
malignancy.
Immunohistochemical localisation of uPA in laryngeal
carcinomas demonstrated intratumoral heterogeneity in the
cellular distribution of the enzyme, more evident in G2 and
G3 tumours. Also, heterogeneous expression of uPA gene
was observed by in situ hybridisation among tumour cells
within the same neoplasm (see Figure 4c). This may reflect
the heterogeneity in cell population typical for most
malignant neoplasms (Skriver et al., 1984; Kristensen et al.,
1990) and may be related to focal dissolution of the basement
membrane observed in these tumours (Antonelli et al., 1991).
In apparent contrast with these observations is the more
homogeneous distribution of uPA positivity in cell nests of
GI tumours. Since the antibodies used in the present study
do not discriminate between active uPA and inactive
proenzyme, it is possible that uPA is present in GI tumours
as inactive pro-uPA that is rapidly converted to the active
form by trace amounts of plasmin during the chromogenic
and SDS-PAGE zymography assays. Also, modifications of
the levels of PA inhibitors may contribute to the final
proteolytic balance of laryngeal carcinomas. Further experi-
ments are required to clarify this point.
Our data demonstrate that parenchymal cells and stromal
cells within the laryngeal tumour produce uPA, thus
suggesting that a complex interplay may exist between both
cell types in generating a profibrinolytic environment in
human laryngeal cancer. uPA gene expression in cultured
oral cavity squamous cell carcinoma cell lines has been
reported previously (Clayman et al., 1993). Also, malignant
cells of cutaneous squamous cell carcinoma express uPA in
situ (Sappino et al., 1991). In contrast, previous studies had
shown that the presence of uPA mRNA in human colon
adenocarcinomas is limited to stromal cells adjacent to
invasive nodules, while tumour cells express uPA-receptor
gene only (Pyke et al., 1991). Taken together, these
observations suggest that the cell localisation of uPA gene
expression can vary among different tumour types and that
tumour cells and/or stromal cells may contribute to the
fibrinolytic balance in human neoplasms.
In conclusion, the present study provides experimental
evidence for a role of uPA in the invasive growth of
squamous cell laryngeal carcinoma. The determination of
uPA antigen in breast cancer tissue extracts has been shown
to represent a significant prognostic factor for disease-free
interval and total survival (Janicke et al., 1990, 1992;
Schmitt et al., 1990; Gr0ndahl-Hansen et al., 1993). Further
studies are required to assess whether uPA up-regulation
also represents a useful prognostic factor for laryngeal
carcinoma.
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